Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies
Frontiers in Pharmacology · 20.08.2026 · 17
DOI: 10.3389/fphar.2026.1897284 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.08.2026. Verfasst von Haiyuan Yue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Second Affiliated Hospital of Lanzhou University, Clinical Medical School, Lanzhou, Gansu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent degenerative joint disorder characterized by progressive cartilage destruction, chronic inflammation, pain, and functional impairment. Conventional therapies primarily focus on symptom management and are unable to restore damaged articular cartilage or effectively modify disease progression. Consequently, increasing attention has been directed toward biologic and regenerative approaches that target the underlying mechanisms of cartilage degeneration and joint dysfunction. This review provides a comprehensive overview of emerging regenerative strategies for articular cartilage repair, including gene- and noncoding RNA-based therapies, platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), mesenchymal stromal cells (MSCs), MSC-derived exosomes, and cell-based interventions. Current evidence indicates that these therapies exert their effects through modulation of inflammatory pathways, enhancement of extracellular matrix synthesis, promotion of chondrocyte survival, and regulation of tissue repair processes. Among them, PRP and BMAC offer minimally invasive approaches with favorable safety profiles, whereas MSCs and exosome-based therapies demonstrate substantial regenerative and immunomodulatory potential. Gene and epigenetic therapies further provide opportunities to target disease-associated molecular pathways and improve cartilage homeostasis. Despite encouraging preclinical and clinical outcomes, significant challenges remain, including heterogeneity in biologic preparations, variability in treatment protocols, limited long-term clinical evidence, and the absence of standardized outcome measures. Future research should focus on mechanistic validation, protocol standardization, optimization of delivery strategies, and large-scale randomized clinical trials to establish the long-term safety and disease-modifying efficacy of these regenerative therapies. Collectively, biologic and regenerative interventions represent promising avenues for advancing cartilage repair and improving clinical outcomes in patients with osteoarthritis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedics, The Second Affiliated Hospital of Lanzhou University, Clinical Medical School, Lanzhou, Gansu, China.
- Orthopaedic Clinical Research Center of Gansu Province, Lanzhou, Gansu, China.
- Intelligent Orthopaedic Industry Technology Center of Gansu Province, Lanzhou, Gansu, China.
- Department of Orthopedics, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Department of Orthopedics, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China.
Zitieren
APA
Yue, H., Alhaskawi, A., Ezzi, S. H. A., & Zhou, J. (2026). Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1897284
Vancouver
Yue H, Alhaskawi A, Ezzi SHA, Zhou J. Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1897284
BibTeX
@article{Yue2026,
author = {Yue, Haiyuan and Alhaskawi, Ahmad and Ezzi, Sohaib Hasan Abdullah and Zhou, Jianwei},
title = {Biologic and regenerative strategies for osteoarthritis: advances in MSC, exosome, and PRP based therapies},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1897284}
}
EUVIMED